Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$113.85 USD

113.85
75,481

-0.01 (-0.01%)

Updated Oct 8, 2024 10:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alnylam's (ALNY) Q3 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Alnylam (ALNY) reports a wider-than-expected loss, while sales beat estimates in the third quarter of 2020.

Regeneron's (REGN) Q3 Earnings & Sales Surpass Estimates

by Zacks Equity Research

Regeneron (REGN) beats on both earnings and sales in the third quarter of 2020 on strong performances by Eylea and Dupixent. Shares rise in pre-market trading.

Incyte (INCY) Q3 Earnings & Sales Miss, Jakafi Demand Strong

by Zacks Equity Research

Incyte (INCY) misses earnings and sales expectations in the third quarter. However, the company's lead drug, Jakafi, reports encouraging growth.

Ionis (IONS) Misses Estimates for Q3 Earnings and Sales

by Zacks Equity Research

Ionis (IONS) posts wider-than-expected Q3 loss. Sales miss estimates.

The Zacks Analyst Blog Highlights: PayPal, Comcast, Novartis, BlackRock and FedEx

by Zacks Equity Research

The Zacks Analyst Blog Highlights: PayPal, Comcast, Novartis, BlackRock and FedEx

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J

Sheraz Mian headshot

Top Analyst Reports for PayPal, Comcast & Novartis

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including PayPal (PYPL), Comcast (CMCSA) and Novartis (NVS).

Kinjel Shah headshot

Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study

by Kinjel Shah

Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results

Incyte (INCY) to Post Q3 Earnings: Will Jakafi Drive Results?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2020 results.

Novartis' (NVS) Q3 Earnings Surpass Estimates, Sales Miss

by Zacks Equity Research

Novartis' (NVS) third-quarter 2020 sales take a hit due to the coronavirus pandemic but earnings beat estimates.

Novartis (NVS) Gets Orphan Drug Tag for Huntington's Disease Drug

by Zacks Equity Research

Novartis (NVS) gets orphan drug designation for branaplam (LMI070) in Huntington's disease.

Is a Beat in Store for Glaxo (GSK) This Earnings Season?

by Zacks Equity Research

Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.

AbbVie (ABBV) Files for Rinvoq in Atopic Dermatitis in US & EU

by Zacks Equity Research

AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Rinvoq ??? atopic dermatitis. The drug is already marketed to treat rheumatoid arthritis.

Gilead's (GILD) CAR T Cell Therapy Gets Positive CHMP Opinion

by Zacks Equity Research

Gilead (GILD) gets positive CHMP opinion for KTE-X19, a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma.

The Zacks Analyst Blog Highlights: Novartis, Zoom Video, FIS, 3M and TOTAL

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novartis, Zoom Video, FIS, 3M and TOTAL

Alnylam (ALNY) Gets Positive CHMP Opinion for Lumasiran

by Zacks Equity Research

Alnylam (ALNY) gets positive opinion from the CHMP for lumasiran for the treatment of primary hyperoxaluria type 1.

Sheraz Mian headshot

Top Research Reports for Novartis, Zoom Video & FIS

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), Zoom Video Communications (ZM) and Fidelity National Information Services (FIS).

Roche's (RHHBY) 9M20 Sales Affected by COVID-19 Outbreak

by Zacks Equity Research

Roche's (RHHBY) performance in the first nine months gets negatively impacted by coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.

Pfizer's (PFE) Ibrance Fails in Early Breast Cancer Study

by Zacks Equity Research

Pfizer's (PFE) Ibrance is marketed for the treatment of HR+, HER2- advanced or metastatic breast cancer but not for any early breast cancer indication.

Model N (MODN) Announces Upbeat Preliminary Results for Q4

by Zacks Equity Research

Model N (MODN) is benefiting from robust adoption of its revenue cloud platform and steady progress in transformation to a SaaS-based model, as reflected in impressive fiscal fourth quarter results.

Here's How J&J (JNJ) Will Roll Out Drug Sector Q3 Earnings

by Zacks Equity Research

J&J's (JNJ) Pharma segment is expected to have performed above market while the Medical Devices segment might have been hurt by the COVID-19 impact in the third quarter.

GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status

by Zacks Equity Research

GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approves New Uses of PFE, JNJ & GSK's Drugs

by Kinjel Shah

New indications of Glaxo's (GSK) Nucala J&J's (JNJ) Simponi Aria and Pfizer's (PFE) Xeljanz get FDA's nod.

Alnylam Releases Positive Top-Line Rare Disease Lumasiran Data

by Zacks Equity Research

Alnylam (ALNY) releases positive top-line data from the ILLUMINATE-B pediatric phase III study of lumasiran, in development for the treatment of PH1.

Blueprint Medicines Rises YTD on Robust Ayvakit Progress

by Zacks Equity Research

Blueprint Medicines' (BPMC) lead drug Ayvakyt/Ayvakit approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's efforts to expand the drug's label are promising as well.